Minority report: the intestinal mycobiota in systemic infections

Thierry Rolling; Tobias M Hohl; Bing Zhai

doi:10.1016/j.mib.2020.05.004

Minority report: the intestinal mycobiota in systemic infections

Standard

Minority report: the intestinal mycobiota in systemic infections. / Rolling, Thierry; Hohl, Tobias M; Zhai, Bing.

In: CURR OPIN MICROBIOL, Vol. 56, 08.2020, p. 1-6.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Rolling, T, Hohl, TM & Zhai, B 2020, 'Minority report: the intestinal mycobiota in systemic infections', CURR OPIN MICROBIOL, vol. 56, pp. 1-6. https://doi.org/10.1016/j.mib.2020.05.004

APA

Rolling, T., Hohl, T. M., & Zhai, B. (2020). Minority report: the intestinal mycobiota in systemic infections. CURR OPIN MICROBIOL, 56, 1-6. https://doi.org/10.1016/j.mib.2020.05.004

Vancouver

Rolling T, Hohl TM, Zhai B. Minority report: the intestinal mycobiota in systemic infections. CURR OPIN MICROBIOL. 2020 Aug;56:1-6. https://doi.org/10.1016/j.mib.2020.05.004

Bibtex

@article{3cc7464a1f2e4ef8859a1ebc6558c475,

title = "Minority report: the intestinal mycobiota in systemic infections",

abstract = "Compared to bacteria, fungi often exhibit a lower abundance and a higher temporal volatility in the intestinal microbiota. Analysis of fungi in the microbiota (mycobiota) faces technical limitations with tools that were originally developed for analyzing bacteria. Dysbiotic states of the intestinal mycobiota, often associated with disruption of the healthy bacterial microbiota, are characterized by overgrowth (domination) of specific fungal taxa and loss of diversity. Intestinal domination by Candida species has been shown to be a major source of Candida bloodstream infections. Fungal dysbiosis is also linked to the development and treatment response in non-fungal infections, for example Clostridioides difficile colitis and HIV. Further research is needed to define the contribution of intestinal mycobiota to human fungal and non-fungal infections.",

author = "Thierry Rolling and Hohl, {Tobias M} and Bing Zhai",

year = "2020",

month = aug,

doi = "10.1016/j.mib.2020.05.004",

language = "English",

volume = "56",

pages = "1--6",

}

RIS

TY - JOUR

T1 - Minority report: the intestinal mycobiota in systemic infections

AU - Rolling, Thierry

AU - Hohl, Tobias M

AU - Zhai, Bing

PY - 2020/8

Y1 - 2020/8

N2 - Compared to bacteria, fungi often exhibit a lower abundance and a higher temporal volatility in the intestinal microbiota. Analysis of fungi in the microbiota (mycobiota) faces technical limitations with tools that were originally developed for analyzing bacteria. Dysbiotic states of the intestinal mycobiota, often associated with disruption of the healthy bacterial microbiota, are characterized by overgrowth (domination) of specific fungal taxa and loss of diversity. Intestinal domination by Candida species has been shown to be a major source of Candida bloodstream infections. Fungal dysbiosis is also linked to the development and treatment response in non-fungal infections, for example Clostridioides difficile colitis and HIV. Further research is needed to define the contribution of intestinal mycobiota to human fungal and non-fungal infections.

AB - Compared to bacteria, fungi often exhibit a lower abundance and a higher temporal volatility in the intestinal microbiota. Analysis of fungi in the microbiota (mycobiota) faces technical limitations with tools that were originally developed for analyzing bacteria. Dysbiotic states of the intestinal mycobiota, often associated with disruption of the healthy bacterial microbiota, are characterized by overgrowth (domination) of specific fungal taxa and loss of diversity. Intestinal domination by Candida species has been shown to be a major source of Candida bloodstream infections. Fungal dysbiosis is also linked to the development and treatment response in non-fungal infections, for example Clostridioides difficile colitis and HIV. Further research is needed to define the contribution of intestinal mycobiota to human fungal and non-fungal infections.

U2 - 10.1016/j.mib.2020.05.004

DO - 10.1016/j.mib.2020.05.004

M3 - SCORING: Review article

C2 - 32599521

VL - 56

SP - 1

EP - 6

ER -